[{"orgOrder":0,"company":"Wits Health Consortium","sponsor":"Regents of the University of California | University of Cape Town | Perinatal HIV Research Unit, Witswatersrand","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"||ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wits Health Consortium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Wits Health Consortium \/ Regents of the University of California | University of Cape Town | Perinatal HIV Research Unit, Witswatersrand","highestDevelopmentStatusID":"10","companyTruncated":"Wits Health Consortium \/ Regents of the University of California | University of Cape Town | Perinatal HIV Research Unit, Witswatersrand"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res France","sponsor":"Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"||ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res France","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res France \/ Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development","highestDevelopmentStatusID":"10","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res France \/ Partners in Health | Harvard Medical School (HMS and HSDM) | Epicentre | Institute of Tropical Medicine, Belgium | Socios En Salud, Peru | Interactive Research and Development"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"||ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Eravacycline","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetraphase Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tetraphase Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Achaogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Plazomicin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Achaogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achaogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achaogen \/ Undisclosed"},{"orgOrder":0,"company":"DongWha Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Zabofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Undisclosed","graph2":"Phase I","graph3":"DongWha Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DongWha Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"DongWha Pharm \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"First Affiliated Hospital of Xinjiang Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"TNP-2092","moa":"||Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"TenNor Therapeutics \/ First Affiliated Hospital of Xinjiang Medical University","highestDevelopmentStatusID":"7","companyTruncated":"TenNor Therapeutics \/ First Affiliated Hospital of Xinjiang Medical University"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Peking Union Medical College Hospital | Nanfang Hospital, Southern Medical University | Third Affiliated Hospital of Third Military Medical University | The First Affiliated Hospital with Nanjing Medical University | Centers for Disease Control and Preven","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"||Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Peking Union Medical College Hospital | Nanfang Hospital, Southern Medical University | Third Affiliated Hospital of Third Military Medical University | The First Affiliated Hospital with Nanjing Medical University | Centers for Disease Control and Preven","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Peking Union Medical College Hospital | Nanfang Hospital, Southern Medical University | Third Affiliated Hospital of Third Military Medical University | The First Affiliated Hospital with Nanjing Medical University | Centers for Disease Control and Preven"},{"orgOrder":0,"company":"UMC Utrecht","sponsor":"Australian and New Zealand Intensive Care Research Centre | Medical Research Institute of New Zealand | Unity Health | Berry Consultants | Global Coalition for Adaptive Research | University of Pittsburgh Medical Center | Intensive Care National Audit & R","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UMC Utrecht","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMC Utrecht \/ Australian and New Zealand Intensive Care Research Centre | Medical Research Institute of New Zealand | Unity Health | Berry Consultants | Global Coalition for Adaptive Research | University of Pittsburgh Medical Center | Intensive Care National Audit & R","highestDevelopmentStatusID":"10","companyTruncated":"UMC Utrecht \/ Australian and New Zealand Intensive Care Research Centre | Medical Research Institute of New Zealand | Unity Health | Berry Consultants | Global Coalition for Adaptive Research | University of Pittsburgh Medical Center | Intensive Care National Audit & R"},{"orgOrder":0,"company":"UConn Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UConn Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UConn Health \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Meropenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vibegron","moa":"||Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"IUATLD","sponsor":"Medical Research Council | Institute of Tropical Medicine, Belgium | Liverpool School of Tropical Medicine | Rede TB","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clofazimine","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IUATLD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IUATLD \/ Medical Research Council | Institute of Tropical Medicine, Belgium | Liverpool School of Tropical Medicine | Rede TB","highestDevelopmentStatusID":"10","companyTruncated":"IUATLD \/ Medical Research Council | Institute of Tropical Medicine, Belgium | Liverpool School of Tropical Medicine | Rede TB"},{"orgOrder":0,"company":"Beijing Chest Hospital","sponsor":"Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Isoniazid","moa":"||Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Beijing Chest Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Chest Hospital \/ Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr","highestDevelopmentStatusID":"11","companyTruncated":"Beijing Chest Hospital \/ Hubei Provincial Center for Disease Control and Prevention | Centre for Tuberculosis Control of Guangdong Province | Hunan Institute For Tuberculosis Control | Anhui Chest Hospital | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Contr"},{"orgOrder":0,"company":"LifeBridge Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"LifeBridge Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Gel","sponsorNew":"LifeBridge Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LifeBridge Health \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Carbohydrate","year":"2014","type":"Inapplicable","leadProduct":"Sodium Carboxymethylcellulose","moa":"||Human corneal endothelial cells","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Boston University","sponsor":"Westat | University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Delamanid","moa":"||Mycobacterium tuberculosis H37Rv","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boston University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston University \/ Westat | University of Florida","highestDevelopmentStatusID":"10","companyTruncated":"Boston University \/ Westat | University of Florida"},{"orgOrder":0,"company":"Boston University","sponsor":"Novartis Pharmaceuticals Corporation | Pfizer Inc | Otsuka Pharmaceutical | University of California, San Francisco | Westat | National Institute of Allergy and Infectious Diseases | University of Colorado, Denver | Harvard Medical School (HMS and HSDM) |","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Delamanid","moa":"||Mycobacterium tuberculosis H37Rv","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boston University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston University \/ Novartis Pharmaceuticals Corporation | Pfizer Inc | Otsuka Pharmaceutical | University of California, San Francisco | Westat | National Institute of Allergy and Infectious Diseases | University of Colorado, Denver | Harvard Medical School (HMS and HSDM) |","highestDevelopmentStatusID":"10","companyTruncated":"Boston University \/ Novartis Pharmaceuticals Corporation | Pfizer Inc | Otsuka Pharmaceutical | University of California, San Francisco | Westat | National Institute of Allergy and Infectious Diseases | University of Colorado, Denver | Harvard Medical School (HMS and HSDM) |"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Amoxicillin","moa":"||NFkB","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Asofarma de M\u00e9xico","sponsor":"Hospital \u00c1ngeles, Cl\u00ednica Londres, Mexico City | Centro InmunoQ | Torre Mayo | Hospital \u00c1ngeles Metropolitano, Mexico City | Centro M\u00e9dico ABC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MEXICO","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Asofarma de M\u00e9xico","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asofarma de M\u00e9xico \/ Hospital \u00c1ngeles, Cl\u00ednica Londres, Mexico City | Centro InmunoQ | Torre Mayo | Hospital \u00c1ngeles Metropolitano, Mexico City | Centro M\u00e9dico ABC","highestDevelopmentStatusID":"10","companyTruncated":"Asofarma de M\u00e9xico \/ Hospital \u00c1ngeles, Cl\u00ednica Londres, Mexico City | Centro InmunoQ | Torre Mayo | Hospital \u00c1ngeles Metropolitano, Mexico City | Centro M\u00e9dico ABC"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"Searle Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ Searle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Aga Khan University \/ Searle Pharmaceuticals"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase||Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Bacterial ribosome||Topoisomerase IV | DNA gyrase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Amgen Inc \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Forest Laboratories"},{"orgOrder":0,"company":"Shanxi Zhendong Pharmacy Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CHINA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Dental and Oral Health","graph2":"Phase IV","graph3":"Shanxi Zhendong Pharmacy Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanxi Zhendong Pharmacy Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanxi Zhendong Pharmacy Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Dr Cipto Mangunkusumo General Hospital","sponsor":"Astellas Pharma | PharOS Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Dr Cipto Mangunkusumo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr Cipto Mangunkusumo General Hospital \/ Astellas Pharma | PharOS Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Dr Cipto Mangunkusumo General Hospital \/ Astellas Pharma | PharOS Ltd"},{"orgOrder":0,"company":"University of Karachi","sponsor":"Merck & Co | Center for bioequivalence studies and clinical reseach, ICCBS, University of Karachi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"PAKISTAN","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Karachi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Karachi \/ Merck & Co | Center for bioequivalence studies and clinical reseach, ICCBS, University of Karachi","highestDevelopmentStatusID":"6","companyTruncated":"University of Karachi \/ Merck & Co | Center for bioequivalence studies and clinical reseach, ICCBS, University of Karachi"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MALAYSIA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National University of Malaysia \/ Santen Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"National University of Malaysia \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MALAYSIA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"National University of Malaysia \/ Santen Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"National University of Malaysia \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MALAYSIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"National University of Malaysia \/ Santen Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"National University of Malaysia \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiGen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"NTC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NTC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NTC \/ Undisclosed"},{"orgOrder":0,"company":"NTC","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NTC \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"NTC \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"NTC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"NTC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NTC \/ Undisclosed"},{"orgOrder":0,"company":"National Liver Institute, Egypt","sponsor":"Future Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"National Liver Institute, Egypt","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Liver Institute, Egypt \/ Future Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"National Liver Institute, Egypt \/ Future Pharmaceutical Industries"},{"orgOrder":0,"company":"Damascus Hospital","sponsor":"UNIPHARMA. Universal Pharmaceutical Industries | Ibn Alhaytham Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SYRIA","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Damascus Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Damascus Hospital \/ UNIPHARMA. Universal Pharmaceutical Industries | Ibn Alhaytham Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Damascus Hospital \/ UNIPHARMA. Universal Pharmaceutical Industries | Ibn Alhaytham Pharma"},{"orgOrder":0,"company":"Deva Holding AS","sponsor":"TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti. | TC Erciyes University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Deva Holding AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deva Holding AS \/ TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti. | TC Erciyes University","highestDevelopmentStatusID":"10","companyTruncated":"Deva Holding AS \/ TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti. | TC Erciyes University"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Canadian Institutes of Health Research | St. Paul's Hospital | Vancouver General Hospital | University of Alberta | University of Manitoba | University Health Network, Toronto | Unity Health Toronto | St. Joseph's Healthcare Hamilton | London Health Scien","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Hospital Research Institute \/ Canadian Institutes of Health Research | St. Paul's Hospital | Vancouver General Hospital | University of Alberta | University of Manitoba | University Health Network, Toronto | Unity Health Toronto | St. Joseph's Healthcare Hamilton | London Health Scien","highestDevelopmentStatusID":"11","companyTruncated":"Ottawa Hospital Research Institute \/ Canadian Institutes of Health Research | St. Paul's Hospital | Vancouver General Hospital | University of Alberta | University of Manitoba | University Health Network, Toronto | Unity Health Toronto | St. Joseph's Healthcare Hamilton | London Health Scien"},{"orgOrder":0,"company":"Boston University","sponsor":"National Institute of Allergy and Infectious Diseases | Centers for Disease Control and Prevention | Macleods Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Boston University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston University \/ National Institute of Allergy and Infectious Diseases | Centers for Disease Control and Prevention | Macleods Pharmaceuticals Limited","highestDevelopmentStatusID":"8","companyTruncated":"Boston University \/ National Institute of Allergy and Infectious Diseases | Centers for Disease Control and Prevention | Macleods Pharmaceuticals Limited"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Amgen Inc \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Forest Laboratories"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Cephalosporin","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Gary E. Stein","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Gary E. Stein","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Gary E. Stein"}]
Find Clinical Drug Pipeline Developments & Deals for Levofloxacin
Details :
Levofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Details :
TNP-2092 is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prosthesis-Related Infections.
Details :
Levaquin-Generic (levofloxacin) is a fluoroquinolone antibiotic used to treat infections caused by bacteria. It is indicated for the treatment of pneumonia, acute bacterial sinusitis.
Details :
Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Helicobacter Infections.
Details :
Levofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Levofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Ceftriaxone is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pneumonia, Aspiration.
Details :
The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye drops were as effective as 14-day tobramycin/dexamethasone eye drops to treat ocular inflammation and prevent infection in post-cataract surgery patients.
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
